Ni X, et al. - Experts conducted a meta-analysis to gauge the clinicopathological and prognostic influence of programmed death-ligand 1 (PD-L1). They performed a comprehensive search in PubMed, Embase, the Cochrane Library, Web of Science and the ClinicalTrials.gov for publications about PD-L1 expression in colorectal cancer. In CRC, findings suggested an association of high expression of PD-L1 with low overall survival. They noted a probability of high PD-L1 expression to be a negative factor for patients with CRC. This expression may help to identify patients suitable for anticancer therapy. A positive association of expression of PD-L1 with lymph node metastasis, gender, and tumor location was noted.